

Press Release

Heerlen (NL), 2 November 2017

48E

DSM reports results first nine months 2017

Highlights YTD 2017

- Strong performance in Q3, contributing to very good first nine months
- Sales up 9% to €6,456m, with 8% organic growth
- Adjusted EBITDA up 15% to €1,086m, driven by both Nutrition and Materials
- ROCE up 170 bps to 12.3%
- Adjusted Net profit up 29% to €504m
- Total Net profit of €1,603m, including gain on Patheon disposal of €1,250m
- Outlook 2017 unchanged

Key figures and indicators

in € million	Jan - Sept 2017	Jan - Sept 2016	% Change	Volume	Price/mix	FX	Other
Sales	6,456	5,905	9%	7%	1%	1%	0%
Nutrition	4,151	3,848	8%	6%	1%	1%	0%
Materials	2,132	1,874	14%	8%	5%	0%	1%
Adjusted EBITDA (cont. operations)¹	1,086	947	15%				
Nutrition	786	693	13%				
Materials	369	330	12%				
EBITDA (cont. operations)	1,032	904					
ROCE (%)	12.3%	10.6%					

¹Adjusted EBITDA (and adjusted Net profit) are Alternative Performance Measures (APM's) that reflect continuing operations. See page 11 for definition and reconciliation

CEO statement

Feike Sijbesma, CEO and Chairman of the DSM Managing Board, commented:

“We are pleased to report another strong quarter, resulting in a very good performance during the first nine months. Nutrition and Materials once again delivered organic growth rates well above their respective markets, with particularly good volume growth.

These results demonstrate significantly improved operational and financial performance, well ahead of plan, with all businesses delivering on their ambitious growth initiatives, and we are firmly on track with our cost-reduction and efficiency improvement programs. Furthermore, we successfully divested our share in Patheon ahead of schedule.

DSM confirms its full year 2017 outlook, despite slightly less favorable currency developments. In addition, with all of these developments ahead of plan we are bringing forward our regular strategic review process for the period beyond 2018 and anticipate communicating the results before mid-year 2018, as announced at our September Investor Event.”

Outlook 2017 unchanged

DSM expects to deliver full-year 2017 results above the targets set out in its Strategy 2018, with an EBITDA growth for the year slightly up from high single-digit to double digit, and with a ROCE increase from double digit basis points to over 100 basis points.

Q3 Highlights 2017

- DSM reports another strong quarter in Q3
- Sales up 7% to €2,136m, with 10% organic growth
- Adjusted EBITDA up 13% to €365m
- Nutrition: 8% organic sales growth; Adjusted EBITDA up 12%
- Materials: 9% volume growth; Adjusted EBITDA up 8%

Key figures and indicators

in € million	Q3 2017	Q3 2016	% Change	Volume	Price/mix	FX	Other
Sales	2,136	1,998	7%	9%	1%	-3%	0%
Nutrition	1,373	1,303	5%	9%	-1%	-3%	0%
Materials	706	634	11%	9%	5%	-3%	0%
Adjusted EBITDA (cont. operations)¹	365	323	13%				
Nutrition	258	231	12%				
Materials	128	118	8%				
EBITDA (Cont. operations)	343	301					
ROCE (%)²	12.3%	10.6%					

¹Adjusted EBITDA (and adjusted Net profit) are Alternative Performance Measures (APM's) that reflect continuing operations.

See page 11 for definition and reconciliation

²January up until September

Key figures and indicators

in € million	January - September						
	2017	2016	% Change	Volume	Price/mix	FX	Other
Sales	6,456	5,905	9%	7%	1%	1%	0%
Nutrition	4,151	3,848	8%	6%	1%	1%	0%
Materials	2,132	1,874	14%	8%	5%	0%	1%
Innovation Center	126	126					
Corporate Activities	47	57					

in € million	Q3 2017						
	Q3 2017	Q3 2016	% Change	Volume	Price/mix	FX	Other
Sales	2,136	1,998	7%	9%	1%	-3%	
Nutrition	1,373	1,303	5%	9%	-1%	-3%	
Materials	706	634	11%	9%	5%	-3%	
Innovation Center	42	43					
Corporate Activities	15	18					

in € million	January - September						
	2017	2016	% Change	Q3 2017	Q3 2016	% Change	
Sales	6,456	5,905	9%	2,136	1,998	7%	
Adjusted EBITDA (cont. operations)	1,086	947	15%	365	323	13%	
Nutrition	786	693	13%	258	231	12%	
Materials	369	330	12%	128	118	8%	
Innovation Center	5	2		4	1		
Corporate Activities	-74	-78		-25	-27		
Adjusted EBITDA margin	16.8%	16.0%		17.1%	16.2%		
EBITDA (cont. operations)	1,032	904		343	301		
Adjusted EBIT (cont. operations)	717	601	19%	239	205	17%	
EBIT (cont. operations)	647	546		206	171		
Capital Employed	7,620	7,620					
Average Capital Employed	7,779	7,561					
ROCE (%)	12.3%	10.6%					
Effective tax rate	18.0%	18.5%					
Adjusted net profit, cont. oper.	504	390	29%	166	146	14%	
Net profit - Total DSM	1,603	542	196%	1,291	322	301%	
Adjusted net EPS	2.81	2.17	29%	0.91	0.81	12%	
Net EPS - Total DSM	9.09	3.04		7.34	1.82		
Operating cash flow	619	644	-4%	290	325	-11%	
Capital Expenditures ¹	384	305		134	128		
Net debt	703	2,054					

¹ Cash, net of customer funding

In this report:



- 'Organic sales growth' is the total impact of volume and price/mix;
- 'Total Working Capital' refers to the total of 'Operating Working Capital' and 'non-Operating Working Capital'

Review by Cluster

Nutrition

in € million	January - September			Q3 2017	Q3 2016	% Change
	2017	2016	% Change			
Sales	4,151	3,848	8%	1,373	1,303	5%
Adjusted EBITDA	786	693	13%	258	231	12%
Adjusted EBITDA margin (%)	18.9%	18.0%		18.8%	17.7%	
Adjusted EBIT	575	485	19%	192	159	21%
Capital Employed	5,292	5,384				
Average Capital Employed	5,454	5,334				
ROCE (%)	14.1%	12.1%				
Total Working Capital	1,472	1,492				
Average Total Working Capital as % of Sales	27.3%	28.2%				

Sales development



Nine months 2017 sales increased by 7% organically compared to the same period last year, with 6% volume growth and 1% higher prices.

Nutrition performed strongly as its growth initiatives led to organic growth rates in all its businesses outpacing their respective markets. Animal Nutrition delivered strong volume growth, with exceptionally high volumes in the third quarter. Human Nutrition and Food Specialties continued to deliver good volume growth, despite soft conditions in some end-market segments.



Nine months 2017 Adjusted EBITDA increased by 13% compared to the same period in 2016, mainly driven by volume growth and the contribution of the efficiency and cost improvement programs. Currency and price/mix effects made a small contribution. EBITDA margin year-to-date was 18.9%, versus 18.0% in the same period last year.

Q3 2017 sales was 5% up on prior year with 8% organic growth partly offset by 3% negative currency effects as the Euro strengthened against DSM's other key currencies. The 9% higher volumes were driven by exceptionally strong growth in Animal Nutrition, as well as good growth in Human Nutrition.

Q3 2017 Adjusted EBITDA was up 12% compared to Q3 2016, driven by strong organic growth and the contribution of the improvement programs. Currencies had a small negative effect. The adjusted EBITDA margin was 18.8%, versus 17.7% in Q3 2016.

Animal Nutrition & Health

Sales development



Nine months 2017 sales saw 8% organic growth, fully driven by volumes, significantly outperforming the market. DSM continues to benefit from its ability to address a wide range of species, as well as from its diversified geographic presence, covering all the major growth areas in the world, and its strong forward-integrated premix position. Market conditions were favorable year-to-date, except for Latin America where domestic demand was impacted by weak economic conditions. This weakness was exacerbated in Q2 due to the ‘meat scandal’ in Brazil, severely impacting beef exports. Recently however, these exports have recovered swiftly.


Overall prices were flat, while for some vitamins a positive price effect in the first half of the year was offset by a negative price effect in Q3.

Q3 2017 organic growth was exceptionally strong at 10% driven by 14% higher volumes. All regions were strong. The beef exports market in Brazil staged a rapid recovery, especially in September. Sales also benefitted from positive timing of order effects in Brazil as well as in some other geographies. Furthermore, the reported sales growth is somewhat flattered by the easy comparison with Q3 last year.

Prices had a 4% negative effect, which was largely due to lower comparable prices for some of the vitamins versus 2016, when these prices spiked in the second half of the year.

Human Nutrition & Health

Sales development



Nine months 2017 sales rose 8% with 7% organic growth, driven mainly by volumes.

Year-to-date, Human Nutrition maintained its positive momentum, delivering good sales growth through its growth initiatives despite softness in some of its end-market segments, which became even more pronounced in Q3. Food & Beverages markets are being addressed successfully through tailored premixes. Sales excellence programs as well as the introduction of new product solutions resulted in above-market growth for both multivitamins and fish oil-based omega-3's. The i-Health business has continued its double-digit growth path, whilst early life nutrition remained a strong performer.

Overall, prices were stable, with higher prices for advanced formulations and premixes compensating for somewhat lower contractual prices in early life nutrition.

In Q3 2017, Human Nutrition reported a solid 5% volume growth with good sales in all segments. Early Life Nutrition had a particularly strong quarter due to high demand for China where markets still show some volatility due to the new regulations coming into effect next year.

Prices were up by 4%, of which a substantial part was due to positive mix effects.

Food Specialties

Food Specialties continued to perform well, both over the first nine months and in Q3 2017, although growth was hampered by some capacity constraints in enzymes. Savory Ingredients performed particularly well.

Materials

in € million	January - September			Q3 2017	Q3 2016	% Change
	2017	2016	% Change			
Sales	2,132	1,874	14%	706	634	11%
Adjusted EBITDA	369	330	12%	128	118	8%
Adjusted EBITDA margin (%)	17.3%	17.6%		18.1%	18.6%	
Adjusted EBIT	275	234	18%	98	86	14%
Capital Employed	1,811	1,798				
Average Capital Employed	1,814	1,763				
ROCE (%)	20.2%	17.7%				
Total Working Capital	368	333				
Average Total Working Capital as % of Sales	12.3%	12.5%				

Sales development



Sadly, we had to report a tragic accident at our Augusta (GA, USA) plant on 27 September 2017 where a contractor lost his life. It once again stresses that in all our activities our utmost priority has to remain the safety and health of our employees and contractors worldwide.

Nine months 2017 sales were up 14% versus the same period last year. Strong growth in specialties was the main driver behind the 13% organic growth, of which 8% was volume growth.

- **DSM Engineering Plastics** showed solid growth overall with good growth in the higher margin specialties for automotive and E&E;
- **DSM Dyneema** delivered continued strong growth especially in personal protection solutions;
- **DSM Resins & Functional Materials** reported continued strong growth in all segments driven by sustainability-driven substitution and improved conditions in Building & Construction markets.

The 5% price effect in the first nine months fully reflects increased input costs.

Nine months 2017 Adjusted EBITDA increased by 12% compared with the same period in 2016, driven by higher volumes and the group-wide cost savings and efficiency improvement program. The Adjusted EBITDA margin was strong at 17.3%, versus 17.6% in the same period last year, when DSM still fully benefited from lower input costs.

Q3 2017 sales were up 14% organically with 9% higher volumes. All three businesses showed good growth and performed well.

Q3 2017 Adjusted EBITDA was up 8% compared to Q3 2016. The Adjusted EBITDA margin was 18.1%, versus 18.6% in Q3 2016, despite higher raw materials costs particularly in the Resins business which was confronted with various disruptions in the supply of key intermediates, amongst others by hurricanes in the US. The robust performance demonstrates the improvements achieved in the quality of returns in the Materials businesses over recent years.

Innovation Center

in € million	January - September			Q3 2017	Q3 2016	% Change
	2017	2016	% Change			
Sales	126	126	0%	42	43	-2%
Adjusted EBITDA	5	2		4	1	
Adjusted EBIT	-29	-15		-17	-5	
Capital Employed	552	553				

Nine months 2017 sales showed strong growth in DSM Advanced Solar. DSM Biomedical is also performing well again, with strong underlying growth largely offsetting the gradual discontinuation of a large contract.

Nine months 2017 Adjusted EBITDA includes a one-time positive amount in Q3 2017 related to the release of a liability following the decision to stop a development project, while the Adjusted EBIT includes an impairment loss on the related assets.

Corporate Activities

in € million	January - September		Q3 2017	Q3 2016
	2017	2016		
Sales	47	57	15	18
Adjusted EBITDA	-74	-78	-25	-27
Adjusted EBIT	-104	-103	-34	-35

Nine months 2017 Adjusted EBITDA slightly improved compared to the same period last year as a result of the contribution of the cost savings programs.

Joint Ventures and Associates

Financial overview of DSM's key joint ventures and associates

in € million, based on 100%		January - September			Q3		
		2017	2016	% Change	2017	2016	% Change
DSM Sinochem	Sales	321	329	-2%	104	103	1%
	Adjusted EBITDA%	14%	14%		12%	13%	
ChemicalInvest	Sales	1,475	1,300	13%	479	408	17%
	Adjusted EBITDA%	9%	3%		13%	5%	

- **DSM Sinochem Pharmaceuticals (50% DSM)** - solid financial performance driven by its sustainable antibiotics platforms, while the improved profitability was offset by less favorable currency effects in Q3 2017.
- **ChemicalInvest (35% DSM)** - strongly improved its financial performance, benefitting from favorable market conditions for caprolactam.

Net result contribution of joint ventures / associates

in € million	January - September		Q3	
	2017	2016	2017	2016
DSM Sinochem (50%)	4	5	0	1
Patheon ¹	7	-5	0	5
ChemicalInvest (35%) ²	0	-9	0	1
Other associates / joint ventures	-18	-13	-4	-4
Total before APM adjustments	-7	-22	-4	3
APM adjustments	1,152	217	1,150	228
Share of the profit of associates/joint ventures	1,145	195	1,146	231

¹ DSM's share in Patheon was 49% in H1 2016, and 33.5% up until 15 May 2017. DSM completed the divestment of its share in Patheon on 29 August 2017.

² The positive net result of the first nine months of 2017 was not recognized, as the total equity value of ChemicalInvest year-to-date Q3 2017 is below zero. DSM has no obligation to fund beyond its net interest.

The following APM adjustments were included in the Q3 2017 result of joint ventures and associates:

- On 29 August 2017, the shares in Patheon N.V. were sold to Thermo Fisher Scientific Inc. resulting in a book profit of €1,250 million.
- POET-DSM Advanced Biofuels made good progress, after a period of significant delays throughout the industry. In particular, progress was made in the development of advanced enzymes, which will now be manufactured on-site, as well as in yeast technology. The pre-treatment set-up has recently been re-designed, much improving performance. The delays in the start-up together with the pre-treatment re-design led to an impairment of €65 million.
- Other various impairments on assets of associates of €35 million.

Cash Flow, Capital Expenditures and Financing

in € million	January - September		Q3 2017	Q3 2016
	2017	2016		
Cash from Operating Activities	619	644	290	325
Total Working Capital	1,635	1,528		
Total Working Capital as % of Sales	19.1%	19.1%		
Capital Expenditure (cash, net of customer funding)	384	305	134	128
Net Debt (end of period)	703	2,054		

Cash flow from operating activities amounted to €619 million in the first nine months of 2017, which was below the comparative period in 2016 due to higher working capital reflecting the higher levels of sales.

Total Working Capital amounted to €1,635 million at the end of Q3 2017 compared to €1,528 million at the end of Q3 2016 mainly due to a decrease in non-operating liabilities. Working capital as a percentage of sales amounted to 19.1%, in line with Q3 2016.

Net debt was €703 million compared to €2,054 million end of September 2016. The decrease of €1,351 million was mainly due to the proceeds from the sale of Patheon shares of in total of €1,477 million in Q3 2017, with an additional €58 million hedge income to be received in Q4 2017.

Overview of Alternative Performance Measures (APM) adjustments to EBIT(DA)

In presenting and discussing DSM's financial position, operating results and cash flows, management uses certain alternative performance measures not defined by IFRS. These alternative performance measures should not be viewed in isolation as alternatives to the equivalent IFRS measures and should be used as supplementary information in conjunction with the most directly comparable IFRS measures. Alternative performance measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other companies. For DSM, the most important APM is the application of APM adjustments to the IFRS measures to provide clear reporting on the underlying business developments.

The following overview gives a summary of APM adjustments (for reconciliation see page 13 & 15).

APM adjustments first nine months of 2017:

Nutrition: EBITDA adjustments amounted to -€14 million relating to the profit improvement programs. EBIT adjustments amounted to -€18 million including -€4 million asset impairment.

Materials: EBITDA adjustments amounted to +€1 million (EBIT+€1 million) relating to the release of a litigation provision.

Innovation: EBITDA adjustments amounted to +€1 million relating to the release of a restructuring provision. EBIT adjustments amounted to -€10 million including -€11 million asset impairment.

Corporate Activities: EBITDA adjustments amounted to -€42 million of which -€34 million related to restructuring programs, -€1 million acquisition related costs and -€7 million related to the spin-off of some research activities.

EBIT adjustments amounted to -€43 million including -€1 million asset impairment.

APM adjustments Q3 2017:

Nutrition: EBITDA adjustments amounted to -€5 million (EBIT -€5 million) relating to the profit improvement programs.

Innovation: EBIT adjustments amounted to -€11 million due to an asset impairment.

Corporate Activities: EBITDA adjustments amounted to -€17 million (EBIT -€17 million) of which -€16 million related to restructuring programs and -€1 million acquisition related costs.

Condensed consolidated statement of income for the first nine months

in € million	January - September 2017			January - September 2016		
	Cont. operations	Discont. operations	Total	Cont. operations	Discont. operations	Total
Sales	6,456	0	6,456	5,905	0	5,905
EBITDA	1,032		1,032	904	-28	876
Operating profit (EBIT)	647		647	546	-28	518
Financial income and expense	-93		-93	-96	0	-96
Profit before income tax expense	554	0	554	450	-28	422
Income tax expense	-96		-96	-75	0	-75
Share of the profit of associates/ joint control entities	1,145		1,145	195	0	195
Net profit	1,603	0	1,603	570	-28	542
Of which:						
Profit attributable to non-controlling interests	-7		-7	-5	0	-5
Net profit attributable to equity holders of DSM	1,596	0	1,596	565	-28	537
Dividend on cumulative preference shares	-6	0	-6	-6	0	-6
Net profit available to holders of ordinary shares	1,590	0	1,590	559	-28	531
Average number of ordinary shares (million)			174.9			174.8
Net earnings per share (EPS) (in €)	9.09	0.00	9.09	3.20	-0.16	3.04
Depreciation and amortization	385	0	385	358	0	358
Capital expenditures			331			276
Acquisitions consideration			60			4
Workforce			21,013			20,786 ¹
of which in the Netherlands			3,798			4,026 ¹

¹ Year-end 2016

Reconciliation to Alternative Performance Measures for the first nine months

in € million	January - September 2017			January - September 2016		
	Cont. operations	Discont. operations	Total	Cont. operations	Discont. operations	Total
EBITDA	1,032	0	1,032	904	-28	876
Acquisitions/divestments	8	0	8	-16	28	12
Restructuring	47	0	47	59	0	59
Other	-1	0	-1	0	0	0
Sub-total APM adjustments to EBITDA	54	0	54	43	28	71
Adjusted EBITDA	1,086	0	1,086	947	0	947
Operating profit (EBIT)	647	0	647	546	-28	518
APM adjustments to EBITDA	54	0	54	43	28	71
Impairments of PPE and Intangible assets	16	0	16	12	0	12
Sub-total APM adjustments to operating profit (EBIT)	70	0	70	55	28	83
Adjusted operating profit (EBIT)	717	0	717	601	0	601
Net profit	1,603	0	1,603	570	-28	542
APM adjustments to operating profit (EBIT)	70	0	70	55	28	83
APM adjustments to financial income and expense	0	0	0	0	0	0
Income tax related to APM adjustments	-17	0	-17	-18	0	-18
APM adjustments to share of the profit of associates/joint control entities	-1,152	0	-1,152	-217	0	-217
Sub-total APM adjustments to net profit	-1,099	0	-1,099	-180	28	-152
Adjusted net profit	504	0	504	390	0	390
Net profit available to holders of ordinary shares	1,590	0	1,590	559	-28	531
APM adjustments to net profit	-1,099	0	-1,099	-180	28	-152
Adjusted net profit available to holders of ordinary shares	491	0	491	379	0	379
Average number of ordinary shares (million)			174.9			174.8
Earnings per share (EPS) (in €):						
Net earnings per share	9.09	0.00	9.09	3.20	-0.16	3.04
Adjusted net earnings per share	2.81	0.00	2.81	2.17	0.00	2.17

Condensed consolidated statement of income for the third quarter

in € million	Q3 2017			Q3 2016		
	Cont. operations	Discont. operations		Cont. operations	Discont. operations	
Sales	2,136	0	2,136	1,998	0	1,998
EBITDA	343	0	343	301	-28	273
Operating profit (EBIT)	206	0	206	171	-28	143
Financial income and expense	-31	0	-31	-30	0	-30
Profit before income tax expense	175	0	175	141	-28	113
Income tax expense	-30	0	-30	-22	0	-22
Share of the profit of associates/ joint control entities	1,146	0	1,146	231	0	231
Net profit	1,291	0	1,291	350	-28	322
Of which:						
Profit attributable to non-controlling interests	-5	0	-5	-3	0	-3
Net profit attributable to equity holders of DSM	1,286	0	1,286	347	-28	319
Dividend on cumulative preference shares	-2	0	-2	-1	0	-1
Net profit available to holders of ordinary shares	1,284	0	1,284	346	-28	318
Average number of ordinary shares (million)			174.7	0	0	175.6
Net earnings per share (EPS) (in €)	7.34	0.00	7.34	1.98	-0.16	1.82
Depreciation and amortization	137	0	137	130	0	130
Capital expenditures			134			116
Acquisitions consideration			6			4
Workforce			21,013			20,786
of which in the Netherlands			3,798			4,026

¹ Year-end 2016

Reconciliation to Alternative Performance Measures for the third quarter

in € million	Q3 2017			Q3 2016		
	Cont. operations	Discont. operations		Cont. operations	Discont. operations	
EBITDA	343	0	343	301	-28	273
Acquisitions/divestments	1	0	1	-1	28	27
Restructuring	21	0	21	23	0	23
Other	0	0	0	0	0	0
Sub-total APM adjustments to EBITDA	22	0	22	22	28	50
Adjusted EBITDA	365	0	365	323	0	323
Operating profit (EBIT)	206	0	206	171	-28	143
APM adjustments to EBITDA	22	0	22	22	28	50
Impairments of PPE and Intangible assets	11	0	11	12	0	12
Sub-total APM adjustments to operating profit (EBIT)	33	0	33	34	28	62
Adjusted operating profit (EBIT)	239	0	239	205	0	205
Net profit	1,291	0	1,291	350	-28	322
APM adjustments to operating profit (EBIT)	33	0	33	34	28	62
APM adjustments to financial income and expense	0	0	0	0	0	0
Income tax related to APM adjustments	-8	0	-8	-10	0	-10
APM adjustments to share of the profit of associates/joint control entities	-1,150	0	-1,150	-228	0	-228
Sub-total APM adjustments to net profit	-1,125	0	-1,125	-204	28	-176
Adjusted net profit	166	0	166	146	0	146
Net profit available to holders of ordinary shares	1,284	0	1,284	346	-28	318
APM adjustments to net profit	-1,125	0	-1,125	-204	28	-176
Adjusted net profit available to holders of ordinary shares	159	0	159	142	0	142
Average number of ordinary shares (million)			174.7			175.6
Earnings per share (EPS) (in €):						
Net earnings per share	7.34	0.00	7.34	1.98	-0.16	1.82
Adjusted net earnings per share	0.91	0.00	0.91	0.81	0.00	0.81

Condensed Consolidated Statement of Comprehensive Income

in € million	January -September	
	2017	2016
Items that will not be reclassified to profit or loss		
Remeasurements of Defined Benefit Pension Plans	67	7
FX on Translation of Foreign Operations Related to Non-Controlling Interest	-8	-3
Equity accounted investees - share of Other comprehensive income		
Items that may subsequently be reclassified to profit or loss		
FX on Translation of Foreign Operations	-526	-65
Change in Fair Value Reserve	-5	3
Change in Hedging Reserve	52	14
Equity accounted investees - share of Other comprehensive income	5	-4
Other Comprehensive Income (before tax)	-415	-48
Income Tax Expense	-23	-3
Other Comprehensive Income (net of tax)	-438	-51
Profit for the Period	1,603	542
Total Comprehensive Income	1,165	491

Condensed Consolidated Statement of Changes in Equity

in € million	January -September	
	2017	2016
Total Equity (at beginning of the period)	6,180	5,631
Changes:		
Total Comprehensive Income	1,165	491
Dividend	-322	-298
Repurchase of Shares	-257	-177
Proceeds from Re-issue of Ordinary Shares	193	251
Other Changes	-5	28
Total Equity (end of period)	6,954	5,926

Condensed Consolidated Balance Sheet - Assets

in € million	30 Sept. 2017	YE 2016
Intangible Assets	2,935	3,188
Property, Plant & Equipment	3,151	3,325
Deferred Tax Assets	294	355
Share in Associates & Joint Ventures	203	586
Financial derivatives	8	0
Other Financial Assets	470	463
Non-Current Assets	7,061	7,917
Inventories	1,835	1,800
Trade Receivables	1,585	1,504
Income tax receivables	59	62
Other Current Receivables	108	87
Financial Derivatives	95	40
Current Investments	1,010	944
Cash & Cash Equivalents	1,606	604
Current Assets	6,298	5,041
Total Assets	13,359	12,958

Condensed Consolidated Balance Sheet - Equity and Liabilities

in € million	30 Sept. 2017	YE 2016
Shareholders' Equity	6,857	6,072
Non-controlling interest	97	108
Equity	6,954	6,180
Deferred Tax Liabilities	257	278
Employee Benefits Liabilities	398	490
Provisions	156	128
Borrowings	2,547	2,552
Financial derivatives	5	14
Other Non-current Liabilities	152	158
Non-current liabilities	3,515	3,620
Employee Benefits	38	40
Provisions	30	54
Borrowings	793	853
Financial Derivatives	77	239
Trade Payables	1,397	1,376
Income tax payable	72	56
Other Current Liabilities	483	540
Current Liabilities	2,890	3,158
Total Equity and Liabilities	13,359	12,958

in € million	30 Sept. 2017	YE 2016
Capital Employed, continuing operations	7,620	7,889
Equity/Total Assets	52%	48%
Net Debt	703	2,070
Operating Working Capital - Continuing Operations	2,023	1,928
OWC/Net Sales - Continuing Operations	23.7%	23.9%
Total Working Capital - Continuing Operations	1,635	1,481
Total WC/Net Sales - Continuing Operations	19.1%	18.4%

Condensed Consolidated Cash Flow Statement

in € million	January - September	
	2017	2016
Cash, Cash Equivalents and Current Investments (at beginning of period)	1,548	674
Current Investments (at beginning of period)	944	9
Cash & Cash Equivalents (at beginning of period)	604	665
Operating Activities		
EBITDA	1,032	876
Change in Working Capital	-311	-171
Income Tax	-51	-54
Other	-51	-7
Cash provided by Operating Activities (Operating cash flow)	619	644
Investing Activities		
Capital Expenditures	-384	-306
Payments regarding drawing rights	-6	-17
Acquisitions	-58	1
Disposal of Subsidiaries, Businesses & Associates	1,467	77
Disposal of Other Non-current Assets	19	4
Change in Fixed-term Deposits	-88	-766
Interest Received	8	14
Dividend and capital (re)payments	-73	124
Other	21	-11
Cash used in Investing Activities	906	-880
Dividend	-199	-186
Interest Paid	-55	-77
Repurchase of shares	-252	-177
Proceeds from re-issued treasury shares	62	135
Change in Commercial Paper	0	-150
Proceeds from / repayments of corporate bonds	0	747
Other Cash from/ used in Financing Activities	-58	-1
Cash from / used in Financing Activities	-502	291
Exchange Differences	-21	-6
Cash and Cash Equivalents (end of period)	1,606	714
Current Investment (end of period)	1,010	774
Cash and Cash Equivalents & Current Investments (end of period)	2,616	1,488

Geographical Information

January - September 2017	The Netherlands	Rest of Western Europe	Eastern Europe	North America	Latin America	China	India	Japan	Rest of Asia	Rest of the World	Total
Net Sales by Origin											
in € million	1,645	1,896	127	1,132	501	755	64	90	193	53	6,456
in %	25	29	2	18	8	12	1	1	3	1	100
Net Sales by Destination											
in € million	224	1,573	410	1,449	784	811	152	223	632	198	6,456
in %	4	24	6	22	12	13	2	4	10	3	100
Total Assets (total DSM) in € million	5,396	2,443	130	2,790	832	1,053	91	148	371	105	13,359
Workforce (headcount, end of period)	3,798	4,906	481	3,266	2,076	4,630	520	196	862	278	21,013
January -September 2016											
Net Sales by Origin											
in € million	1,507	1,809	118	1,092	396	600	56	66	212	49	5,905
in %	26	31	2	18	7	10	1	1	3	1	100
Net Sales by Destination											
in € million	229	1,419	367	1,359	734	703	134	189	589	182	5,905
in %	4	25	6	23	12	12	2	3	10	3	100
year-end 2016:											
Total Assets in € million	4,560	2,495	126	3,110	885	1,077	87	144	367	107	12,958
Workforce (headcount)	4,026	4,715	439	3,187	2,069	4,594	475	193	828	260	20,786

Notes to the condensed financial statements

Accounting policies and presentation

The consolidated financial statements of DSM for the year ended 31 December 2016 were prepared according to International Financial Reporting Standards (IFRS) as adopted by the European Union and valid as of the balance sheet date. These accounting policies are applied in the current interim financial statements that are in compliance with IAS 34 'Interim Financial Reporting' and need to be read in conjunction with the Integrated Annual Report 2016 and the discussion by the Managing Board earlier in this interim report.

Audit

These interim financial statements have not been audited.

Risks and uncertainties

DSM has a risk management system in place. A description of the system and an overview of potentially important risks for DSM is provided in the Integrated Annual Report 2016 and in the governance section on www.dsm.com. DSM has reviewed the developments and incidents in the first half of 2017 and assessed the risks for the year. On the basis of these assessments DSM has concluded that the most important risks and responses reported in the Integrated Annual Report 2016 are still applicable.

Seasonality

In cases where businesses are significantly affected by seasonal or cyclical fluctuations in sales, this is discussed in the 'Review by Cluster' earlier in this report.

Scope of the consolidation

There were no material changes in the scope of consolidation until the third quarter of 2017 other than the transaction mentioned below.

In Q1 2017, DSM acquired 'Sunshine' (Suzhou Sunshine New Materials Technology Co., Ltd), active in high performance solar photovoltaic back sheets. Effective date of acquisition was 3 January 2017. In accordance with IFRS 3, the purchase price of Sunshine was allocated to identifiable assets and liabilities acquired. Goodwill amounted to €17 million and relates to expected synergies from integrating Sunshine into the DSM Advanced Solar operations.

The acquisition contributed €4 million to net sales and a loss of €2 million (EBIT) to the result in the first three quarters of 2017.

Acquisition of Suzhou Sunshine	
<i>in € million</i>	fair value
Intangible assets	23
Property, plant and equipment	1
Inventories	1
Receivables and Other current assets	1
Cash and cash equivalents	1
Total Assets	27
Non-current liabilities	5
Current liabilities	2
Total liabilities	7
Net assets at fair value	20
Total consideration	37
Preliminary goodwill	17

Dividends and equity

On 26 May 2017, the final dividend of €1.20 per share for the year 2016 was paid to holders of ordinary shares and a dividend of €0.14 per share was paid to holders of cumulative preference shares A. The total distribution to shareholders amounting to €216 million was recorded against retained earnings. An interim dividend for 2017 of €0.58 per ordinary share and €0.06 for cumulative preference shares A was recognized as a liability in the second quarter of 2017. This distribution to shareholders amounting to €104 million took place on 24 August 2017. In the first 9 months of 2017, 3.4 million shares were released into circulation in connection with stock dividend, the exercise of options and delivery of performance shares, 4.0 million shares were repurchased in the same period.

Heerlen, 2 November 2017
The Managing Board

Feike Sijbesma, CEO/Chairman
Geraldine Matchett, CFO
Dimitri de Vreeze, member

Financial calendar

14 February 2018	Publication of full year results of 2017
8 May 2018	Publication of the results of the first three months of 2018
9 May 2018	Annual General Meeting of Shareholders
1 August 2018	Publication of the half year results of 2018
31 October 2018	Publication of the results of the first nine months of 2018

Contact Information

Investor Relations

Dave Huizing

t. +31 (0) 45 578 28 64

e. investor.relations@dsm.com

Media Relations

Stephen Hufton

t. +31 (0) 45 578 7029

e. media.contacts@dsm.com

Additional Information

Today DSM will hold a conference call for media at 08:00 and a conference call for **investors and analysts** at 09:00. Details on how to access these calls can be found on the DSM website, www.dsm.com.

DSM - Bright Science. Brighter Living.™

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at www.dsm.com.

Find us on:    

Forward Looking Statement

This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law.